13F Holdings
中文EN

BHVN Biohaven Ltd.

Pharmaceutical Preparations · NYSE · SEC CIK 1935979 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY30.4%
TTM EPS YoY49.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-161.3%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets137.3%
Debt / equity—
Current ratio3.05x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.87x
Accruals ratio-20.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$635.07M$795.87M$373.28M$437.07M$181.49M
SG&A expense$110.31M$89.24M$62.77M$130.86M$37.41M
Operating income-$745.38M-$885.11M-$436.05M-$567.93M-$218.90M
Pretax income-$737.38M-$845.69M-$409.55M-$569.84M-$212.43M
Income tax$1.44M$735,000-$1.38M$438,000$1.37M
Net income-$738.82M-$846.42M-$408.17M-$570.28M-$213.80M
EBITDA-$735.46M-$877.26M-$429.14M-$566.55M-$217.51M
EPS (basic)-6.86-9.28-5.73-12.75-5.43
EPS (diluted)-6.86-9.28-5.73-12.75-5.43
Weighted avg. shares (diluted)107.62M91.23M71.20M44.74M39.38M
Balance sheet
Cash & equivalents$229.96M$102.54M$248.40M$242.60M$77.06M
Short-term investments$89.18M$386.86M$133.42M$260.46M$0
Current assets$368.33M$538.47M$442.45M$586.97M$94.82M
PP&E, net$15.96M$17.32M$17.19M$17.51M$13.01M
Goodwill$1.39M$1.39M$1.39M$1.39M$1.39M
Intangibles$18.40M$18.40M$18.40M$18.40M$18.40M
Total assets$451.45M$615.11M$513.21M$661.78M$142.06M
Current liabilities$115.93M$154.23M$55.42M$90.02M$41.94M
Total liabilities$399.38M$191.67M$85.24M$123.01M$47.37M
Shareholders' equity$52.07M$423.44M$427.98M$538.77M$34.69M
Shares outstanding132.78M101.22M81.12M68.19M0
Cash flow statement
Operating cash flow-$609.44M-$582.45M-$331.73M-$297.69M-$145.84M
Capital expenditure$715,000$4.05M$3.05M$6.07M$938,000
Free cash flow-$610.15M-$586.50M-$334.77M-$303.76M-$146.78M
Investing cash flow$300.56M-$244.97M$129.83M-$304.79M$944,000
Financing cash flow$439.12M$677.77M$211.91M$767.60M$138.45M
Depreciation & amortization$9.92M$7.86M$6.91M$1.39M$1.39M
Stock-based compensation$112.36M$71.96M$28.79M$193.56M$65.64M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.